Rob Dillard

DocwireNews

Causes of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) differ according to their CLL-International Prognostic Index (IPI) risk group, according to a study presented as part of the 2020 ASCO Virtual Scientific Program.Researchers used the Mayo Clinic CLL database to recruit 1,276 patients (median age at diagnosis, 63 years; 69% male) diagnosed with CLL between January 2000 and December 2019 who were evaluated within one year of diagnosis. They assessed incidences of cause-specific death using Gray&rsquo;s test, and categorized deaths from different causes treated as competing events and excluded any deaths from unknown causes.Based on CLL-IPI scores, researchers observed that 35% of CLL patients had low-risk disease, 35% had intermediate-risk disease, and 30% had high- and very-high-risk disease, respectively. During a mean follow-up of six years, 286 mortalities occurred. Of those, cause of death was CLL progression in 35% of patients, infection in 6%, second malignancy in 16%, CLL-unrelated in 21%, and unknown in 23%. Results showed that rates of death due to CLL progression were higher (17.3% at five years; 30.3% at 10 years) than the rates due to CLL-related complications (5.7% at five years; 12.9% at 10 years) or due to CLL-unrelated causes (8.6% at five years; 16.9% at 10 years) in the CLL-IPI high- and very-high-risk group, but not the CLL-IPI low- or intermediate-risk group. The investigators found that the CLL-IPI risk group was linked with a higher rate of death due to CLL progression (P&lt;0.001), as well as a higher rate of death due to CLL-related complications (P=0.013) and CLL-unrelated causes (P&lt;0001).&ldquo;In patients with high- and very-high-risk CLL, improving CLL disease control with novel agents seems justified. In patients with low- and intermediate-risk CLL, there should be increased efforts to reverse immune dysfunction to reduce infections and second malignancies,&rdquo; the authors concluded.Wang Y, et al. Cause of Death in Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) stratified by the CLL-International Prognostic Index (CLL-IPI). Presented at the 2020 ASCO Virtual Scientific Program; May 29-31, 2020.

MarkAlain Déry, DO

The Significant Danger Measles Pose for Unvaccinated Children

Infectious Disease

Andrew Moreno

Antithrombotic Care in Hemophilia: A Summary of Multi-Organizational Clinical Practice Guidance

Hemophilia

James Tumlin, MD

Joel M. Topf, MD, FACP

Proteinuria Remission With Sparsentan in FSGS

NKF Spring Clinical Meetings 2025

Latest News

Assessing Cause of Death in Patients with Newly Diagnosed Chronic Lymphocytic Leukemia

Conference Coverage

Causes of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) differ according to their CLL-International Prognostic Index (IPI) risk group, according to ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe